All In Biotech

Investigational drug · Phase 2

ERAS-0015

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "ERAS-0015"

First trial start

2026

Nov 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ERAS-0015", any sponsor or status.

Conditions studied

As listed on its trial records.

  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • NSCLC
  • RAS Mutation
  • MTAP Deletion
  • Lung Cancer
  • Pancreatic Cancer Metastatic
  • Thoracic Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "ERAS-0015" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for PDAC

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • GEMPhase 35 trials

    Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer

  • AtebimetinibIMM-1-104, Group APhase 34 trials

    Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)

  • zoldonrasibPhase 34 trials

    Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC

  • GFH276Phase 25 trials

    Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)

  • RMC-9805Phase 23 trials

    Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC

  • RNK08954Phase 23 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor Cancer, PDAC, KRAS G12D Mutations

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.